| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1367-5931(98)80121-X |
| P698 | PubMed publication ID | 9736918 |
| P2093 | author name string | J A Shafer | |
| P2860 | cites work | Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs | Q27730421 |
| X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition | Q27734011 | ||
| New inhibitors of thrombin and other trypsin-like proteases: hydrogen bonding of an aromatic cyano group with a backbone amide of the P1 binding site replaces binding of a basic side chain | Q27746325 | ||
| Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). | Q34060107 | ||
| Primary stroke prevention in nonvalvular atrial fibrillation: implementing the clinical trial findings | Q41616246 | ||
| The crystal structure of human alpha-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitor | Q42845972 | ||
| Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group | Q44421412 | ||
| A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement | Q47300350 | ||
| Low-molecular-weight heparin in the treatment of patients with venous thromboembolism | Q47302490 | ||
| Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective | Q47313971 | ||
| Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement | Q47324889 | ||
| A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis | Q47334930 | ||
| A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation | Q47384989 | ||
| The Scylla and Charybdis of oral anticoagulant treatment | Q48940630 | ||
| An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation | Q48940645 | ||
| Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery | Q49167890 | ||
| The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. | Q53361537 | ||
| The Treatment of Proximal Vein Thrombosis with Subcutaneous Low-Mole Molecular-Weight Heparin Compared with Continuous Intravenous Heparin | Q59139683 | ||
| Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo | Q71200603 | ||
| A meta-analysis of methods to prevent venous thromboembolism following total hip replacement | Q71625306 | ||
| Prevention of venous thromboembolism | Q71732662 | ||
| Crystallographic structure of a peptidyl keto acid inhibitor and human α-thrombin | Q71797823 | ||
| Amide and α-keto carbonyl inhibitors of thrombin based on arginine and lysine: Synthesis, stability and biological characterization | Q71797838 | ||
| Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site | Q73183249 | ||
| Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy | Q73388159 | ||
| Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes | Q73442683 | ||
| Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine | Q73707813 | ||
| Genetic association between sensitivity to warfarin and expression of CYP2C9*3 | Q73834859 | ||
| Dibasic benzo[b]thiophene derivatives as a novel class of active site-directed thrombin inhibitors. 1. Determination of the serine protease selectivity, structure-activity relationships, and binding orientation | Q73846913 | ||
| Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position | Q73846959 | ||
| Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position | Q73883120 | ||
| Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on so | Q74177839 | ||
| Characterization of the two-step pathway for inhibition of thrombin by alpha-ketoamide transition state analogs | Q74230747 | ||
| L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor | Q77743915 | ||
| Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor | Q77743989 | ||
| P433 | issue | 4 | |
| P921 | main subject | anticoagulant | Q215118 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 458-465 | |
| P577 | publication date | 1998-08-01 | |
| P1433 | published in | Current Opinion in Chemical Biology | Q15758415 |
| P1476 | title | Cardiovascular chemotherapy: anticoagulants | |
| P478 | volume | 2 |
| Q73022408 | Fluorobenzamidrazone thrombin inhibitors: influence of fluorine on enhancing oral absorption |
| Q58863348 | Protease inhibitors – Part 3. Synthesis of non-basic thrombin inhibitors incorporating pyridinium-sulfanilylguanidine moieties at the P1 site |
| Q33585640 | Small, noncovalent serine protease inhibitors |
| Q35849235 | Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa |
Search more.